## MOH: Molina Healthcare Inc - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.9% in lower entry zone (4.0-10.0%), top 9% cross-sectional ranking. Caution: MRS_5 (-0.9%) diverging from MRS_20, watch for reversal. Outperforming sector by 6.5%. Caution: momentum weakening (-6.3% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($150.84)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Investors to Connect**
- Source: KGET.com | 20251216T160922 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (MOH) who bought securities prior to February 5, 2025. The investigation will determine if Molina and its officers engaged in corporate wrongdoing. The firm encourages affected investors to connect with them for more information, noting there is no cost to them as they operate on a contingency fee basis.

**2. Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Investors to Connect**
- Source: Fox 59 | 20251216T160919 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (NYSE:MOH) securities. The investigation focuses on whether Molina and its officers/directors engaged in corporate wrongdoing. Investors who purchased Molina securities before February 5, 2025, are encouraged to contact the firm to assist with the investigation.

**3. Reassessing Molina Healthcare (MOH): Is the Recent Share Price Rebound Enough to Shift Its Valuation?**
- Source: Sahm | 20251216T041035 | Somewhat-Bullish | Relevance: 100%
- Molina Healthcare (MOH) has seen a significant share price rebound, with shares up 22% this month, despite a 41.3% year-to-date decline. Analysts suggest a fair value near $170, implying the stock is currently undervalued, though this valuation depends on aggressive earnings growth assumptions. Investors are questioning whether the recent bounce fully prices in a recovery or if further upside exists.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Valuation risk: PEG 2.6x with declining EPS estimates leaves no margin for error.
2. Elevated short interest (11.4%): bears positioning against stock.
3. Long-term trend broken: trading 29.5% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.62 signals overvaluation risk, limited margin of safety. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.8B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 11.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.62 |
| Forward P/E | 10.7 |
| Current P/E | 11.7 |
| YoY Growth | 9.4% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 13.2% to 6.9% (-6.3% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 91st percentile. MRS_5 (-0.9%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.1% shows strong absolute momentum above own 20MA. Outperforming sector by 6.5pp, stock-specific strength. Below SMA200 (0.70x), long-term trend not supportive. MACD histogram positive (2.02), confirming momentum. RSI neutral at 58. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.86% (CS: 91) | Strong |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | 2.02 | Bullish |
| vs SMA20 | 1.061x | Above |
| vs SMA50 | 1.018x | Above |
| vs SMA200 | 0.705x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $162.72
- **Stop Loss:** $150.84 (7.3% risk)
- **Target:** $180.54 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 79
- **Position Value:** $12,854.88
- **Portfolio %:** 12.85%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*